Sometimes, dips in immunization quality can be rescued with a little extra quantity.
A new, highly contagious variant could have terrible consequences. But if it ends up causing milder symptoms than Delta, there’s a real upside.
A vaccine’s value isn’t just in its peak performance.
Medical professionals are used to being believed, but as patients, they found that their expertise didn’t matter.
After two years of pandemic waves, we’re finally learning whether the disease has a predictable schedule.
It’s becoming clear that “coinfections” happen all the time. Just how bad are they?
About one in five health-care workers has left their job since the pandemic started. This is their story—and the story of those left behind.
But are they a good idea?
No one knows exactly what the rules are for post-booster behavior.
Turns out, it’s hard to adjust to a new normal when that new normal keeps changing.
We’re avoiding the hardest questions about living with the coronavirus long term.
It’s possible that a good deal of the difference in the shots’ performance can be summed up with a simple phrase: More is better.
With FDA authorization for a kid-size COVID vaccine pending, a pediatrician and infectious-disease expert weighs in on what’s next.
The CDC indicated that it would move toward a hands-off stance: Booster-eligible people should stick with one brand, but may mix and match at will.
We know more than ever about how to use boosters, but still very little about when to use them.
America has a choice to make.
Actually, you’re probably not in quarantine.
The drug, molnupiravir, is named after Thor’s hammer, Mjölnir. But its power depends on reaching the right people, in the right time frame.
For months we’ve been fixated on the idea that some people are at “high risk” and others aren’t. Now scientists have a better understanding of the continuum.
This one is far from over, but the window to prepare for future threats is closing fast.